[A19-17] Encorafenib (melanoma) - Addendum to Commission A18-61
|Commission:||Commission awarded on 2019-02-12 by the Federal Joint Committee (G-BA)|
|Current document:||Addendum to Commission A18-61 (German version) Further documents|
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
|Contact address:||to the contact form|
Encorafenib (melanoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
|2019-03-22||Addendum to Commission A18-61 (German version)||296 kB|
Federal Joint Committee (G-BA)
2019-03-22 A G-BA decision was published.